In recent years, the first-line available therapeutic options for metastatic renal cell carcinoma (mRCC) have radically changed with the introduction into clinical practice of new immune checkpoint inhibitor (ICI)-based combinations. Many efforts are focusing on identifying novel prognostic and predictive markers in this setting. The complement system (CS) plays a central role in promoting the growth and progression of mRCC. In particular, mRCC has been defined as an “aggressive complement tumor”, which encompasses a group of malignancies with poor prognosie and highly expressed complement components. Several preclinical and retrospective studies have demonstrated the negative prognostic role of the complement in mRCC; however, there is little evidence on its possible role as a predictor of the response to ICIs. The purpose of this review is to explore more deeply the physio-pathological role of the complement in the development of RCC and its possible future use in clinical practice as a prognostic and predictive factor.
近年来，随着新型免疫检查点抑制剂联合疗法进入临床实践，转移性肾细胞癌的一线治疗方案发生了根本性变革。当前研究重点聚焦于探索该领域的新型预后与预测标志物。补体系统在促进转移性肾细胞癌生长和进展中发挥核心作用，尤其该疾病被定义为“侵袭性补体肿瘤”——这类恶性肿瘤具有预后差且高表达补体成分的特征。多项临床前及回顾性研究已证实补体在转移性肾细胞癌中的负面预后作用，但其作为免疫检查点抑制剂疗效预测标志物的潜在价值尚缺乏充分证据。本综述旨在深入探讨补体在肾细胞癌发生发展中的病理生理学作用，及其未来作为临床预后与预测因子的应用前景。
肿瘤(癌症)患者之家